“Advances in Prostate Cancer” is an addition to the InTech collection of three previous
books about prostate cancer and aims at providing a comprehensive overview of specific
aspects of the latest research and current knowledge relating to this tumor entity to
scientists and clinicians. For this purpose a series of research articles, clinical investigations
and reviews that deal with a wide range of relevant aspects pertinent to the epidemiology,
diagnosis, patient care, treatment and basic biology of prostate cancer were included.
Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học Radiation Oncology cung cấp cho các bạn kiến thức về ngành y đề tài: "High-dose intensity-modulated radiotherapy for prostate cancer using daily fiducial marker-based position verification: acute and late toxicity in 331 patients...
Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học Radiation Oncology cung cấp cho các bạn kiến thức về ngành y đề tài: " Potentials of on-line repositioning based on implanted fiducial markers and electronic portal imaging in prostate cancer radiotherapy...
Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học Critical Care giúp cho các bạn có thêm kiến thức về ngành y học đề tài: Identification of candidate predictive and surrogate molecular markers for dasatinib in prostate cancer: rationale for patient selection and efficacy monitoring...
Results from the univariate analysis of prostate cancer mortality and incidence do not take
into account the effect of different covariables, which might influence the SMR and SIR.
Various covariables where considered to model longitudinal effects: age, calendar year, year
of immigration, length of stay in Germany; cohort was considered for the analysis of
Multivariate Poisson regression did not show any significant effect of the considered
covariables on mortality (data not shown).
One authorized urologist (M.M.) performed all the operations. We used a standard TURP
setup with an irrigation pressure of 80 cmH2O and an irrigation rate of 250 ml/min using
D-sorbitol solution. After a rough resection of almost all the transition and central zone,
we tried to resect and fulgurate the peripheral zone as completely as possible, especially
where cancer was detected by biopsy. The resection was continued until adipose tissue,
venous sinus or the external sphincter was identified.
PSA (prostate-specific antigen), the most useful serum
marker for prostate cancer, is encoded by thehKLK3gene
and is present in the serumas amixture of several molecular
species. This work was performed to identify the hKLK3
transcripts in order to determine how many proteins
resembling PSA are synthesized from thehKLK3gene and
secreted in blood. Combined Northern blotting, molecular
cloninganddatabase searching showed that thehKLK3gene
produces at least 15 transcripts ranging in size from 0.7 to
6.1 kb. Polysomal distribution analysis revealed that the
transcripts shorter than 3.
Human glandular kallikrein 2 (hK2) is a trypsin-like serine protease expressed predominantly in the prostate epithelium. Recently, hK2 has proven to be a useful marker that can be used in combination with prostate speciﬁc antigen for screening and diagnosis of prostate cancer. The cleavage by hK2 of certain substrates in the proteolytic cascade suggest that the kallikrein may be involved in prostate cancer development; however, there has been very little other progress toward its biochemical characterization or elucidation of its true physiological role.
EDRN is at the forefront of technology-driven research on the use of
biomarkers for the early detection of cancer. By identifying and validat-
ing biomarkers, such as novel proteins or changes in gene expression, it
is possible to measure an individual’s disease risk, progression of disease,
or response to therapy. Ultimately, EDRN research will aid in prevention
and in early therapeutic intervention, based on early detection of disease.
Role of Immunohistochemical Analysis Immunohistochemical stains are peroxidase-labeled antibodies against specific tumor antigens that are used to define tumor lineage. The number of available immunohistochemical stains is ever-increasing.
immunohistochemical stains should be used in conjunction with the patient's clinical presentation and imaging studies to select the best therapy. Communication between the clinician and pathologist is essential.
No stain is 100% specific, and over-interpretation should be avoided.